A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors

Table 5 COX multivariate analyses for OS and PFS

OS	HR	95% CI	P value	PFS	HR	95% CI	P value
High-risk group	3.04	1.64–5.64	< 0.001*	High-risk group	1.79	1.04–3.06	0.035*
Male sex	1.55	0.83–2.90	0.172	Male sex	0.89	0.55–1.46	0.654
Age > 65 years	0.72	0.42–1.24	0.238	Age > 65 years	0.77	0.49–1.19	0.240
PS (WHO) ≥ 1	1.30	0.68–2.50	0.428	PS (WHO) ≥ 1	1.28	0.75–2.17	0.366
Therapy line > 1	1.12	0.63–1.98	0.706	Therapy line > 1	0.98	0.59–1.62	0.939
Nodal metastases	0.93	0.53–1.63	0.789	Nodal metastases	0.89	0.56–1.40	0.608
Lung metastases	0.99	0.57–1.71	0.960	Lung metastases	1.37	0.87–2.16	0.169
Bone metastases	0.91	0.50–1.65	0.751	Bone metastases	1.76	1.05–2.94	0.032*
Liver metastases	2.80	1.55–5.07	0.001*	Liver metastases	1.90	1.12–3.20	0.017*
Brain metastases	2.28	0.97–5.35	0.060	Brain metastases	2.26	1.16–4.43	0.017*

ISSN: 1471-2407